Can dupilumab/dalbitux completely cure atopic dermatitis?

Dupilumab (dupilumab) targets and inhibits the effects of two key immune factors, IL-4 and IL-13, which play a crucial role in the pathogenesis of atopic dermatitis . IL-4 and IL-13 are the main cytokines that regulate Th2 responses in the immune system and can trigger allergic reactions and promote skin inflammation. By inhibiting the effects of these two cytokines, dupilumab can effectively reduce the immune system's overreaction, thereby alleviating the symptoms of atopic dermatitis. Compared with traditional treatment methods, dupilumab can provide more precise and long-term immune regulation, allowing patients to significantly alleviate symptoms.

Based on multiple clinical studies, dupilumab has shown significant efficacy in treating patients with moderate to severe atopic dermatitis. In a study involving 740 adult patients, all received dupilumab or placebo in combination with topical corticosteroids. The results showed that after 16 weeks of treatment, about 39% of patients who received dupilumab had almost complete clearance of atopic dermatitis symptoms, while only 12% of patients in the placebo group had similar effects.

In the other two studies, the efficacy of dupilumab remained significant, particularly among patients who did not receive topical corticosteroids. The study showed that 37% of patients who received dupilumab every two weeks experienced relief or almost complete relief of atopic dermatitis symptoms, compared with only 9% of patients in the placebo group.

Studies on adolescents and children have also shown that dupilumab has significant efficacy in patients of different age groups. For example, in a study of 251 adolescent patients aged 12 to 18 years, after 16 weeks of treatment, about 24% of patients who received dupilumab had complete or almost complete resolution of atopic dermatitis symptoms, compared with only 2% of patients in the placebo group.

Although dupilumab can significantly reduce the symptoms of atopic dermatitis, whether it can “cure” the disease remains a question worthy of concern. Atopic dermatitis is a chronic immune system disease that is often accompanied by an ongoing overreaction of the immune system. Existing clinical studies show that although dupilumab can provide patients with long-term symptom relief, it does not completely eliminate the underlying cause of atopic dermatitis. Symptoms often improve significantly after patients receive treatment, but symptoms may return once treatment is stopped.

As an immunotherapy drug, the therapeutic effect of dupilumab mostly depends on the continued use of the drug. In a study involving children, although symptoms were significantly relieved after 16 weeks of treatment, some patients gradually experienced a recurrence of symptoms once treatment was stopped or discontinued. Therefore, dupilumab is not the final solution to cure atopic dermatitis, but it can achieve long-term symptom relief by controlling the immune response.

Reference materials:https://www.dupixent.com/